GILD Gilead Sciences
- 63.500
- -0.440-0.69%
- 63.630
- +0.130+0.20%
Gilead Sciences News
Gilead Sciences Partners With White House for Early Cancer Detection Program "Biden Cancer Moonshot"
NORTHAMPTON, MA / ACCESSWIRE / May 28, 2024 / Gilead Sciences:In an effort to advance access to cancer prevention and early detection among U.S. workers, the Biden Cancer Moonshot recently announced a
MEDSIR & Debiopharm Initiate Clinical Collaboration to Explore Potential Synergy of Debio 0123 & Sacituzumab Govitecan in Advanced Breast Cancer
The WIN-B is a Phase Ib/II investigator-sponsored trial (IST) that will evaluate the safety and preliminary efficacy of the Debiopharm's potent Wee-1 inhibitor Debio 0123 in combination with Gilead's
Express News | Cartography Biosciences: Will Receive an Upfront Payment of $20 Mln, With Additional Near-Term Preclinical Milestones
Express News | Cartography Biosciences: Strategic Collaboration With Gilead to Develop Oncology Therapies Against Novel Targets and Target Pairs
US and Europe speed up procurement of bird flu vaccine to deal with potential pandemic threat
The United States and Europe are taking steps to purchase or produce H5N1 avian influenza vaccines to protect at-risk poultry and dairy farm workers, vets, and laboratory technicians.
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
Wells Fargo Maintains Gilead Sciences(GILD.US) With Hold Rating, Maintains Target Price $78
Wells Fargo analyst Mohit Bansal maintains $Gilead Sciences(GILD.US)$ with a hold rating, and maintains the target price at $78.According to TipRanks data, the analyst has a success rate of 58.3% and
BMO Capital Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $80
BMO Capital analyst Evan Seigerman maintains $Gilead Sciences(GILD.US)$ with a buy rating, and maintains the target price at $80.According to TipRanks data, the analyst has a success rate of 47.2% and
Analysts' Top Healthcare Picks: Scholar Rock Holding (SRRK), Gilead Sciences (GILD)
Avian flu cases spur retail investors to buy vaccine stocks
The increase in cases of avian influenza triggered investors to rush to buy vaccine stocks, and the stock prices of companies such as CureVac, Novavax, and Moderna soared. Experts recommend investing cautiously, as the development of the epidemic is uncertain.
Gilead Sciences (GILD) Gets a Hold From Wells Fargo
Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024
Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of the Liver (EASL) Congress, June 5-8, 2024 in Milan, Italy. Key findings from more than 25 abstracts will include:
$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 3.07% on an annualized basis producing an average annual return of 11.12%. Currently, Gilead Sciences has a market c
Gilead Sciences Hosts Inaugural Global Health Equity Summit
NORTHAMPTON, MA / ACCESSWIRE / May 21, 2024 / Driven by our purpose to make the world a healthier place for all people, we've worked to improve health equity and advance equitable access to care. Last
Gilead's Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And Associated Itch
Saturday, Gilead Sciences Inc (NASDAQ:GILD), following the recent acquisition of CymaBay Therapeutics Inc, announced interim results from the ongoing ASSURE study.The ASSURE study is an open-label stu
Reported Saturday, Gilead Sciences Announced That The Investigational Seladelpar Shows Significant Improvements In Liver Disease Progression And Itch Reduction In Primary Biliary Cholangitis
- 70% of Patients Receiving Seladelpar 10mg Achieved the Clinically Meaningful Composite Endpoint and 37% Achieved ALP Normalization at 12 Months -- Reduction in Patient-Reported Pruritus (Itching) wa
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements in markers of cholestasis and reduced inflammation. Additional findings demonstrate that seladelpar can help reduce pruritus (itch) in people living with primary biliary cholangitis (PBC).
Gilead (GILD.US) /ArcellX's Next-Generation BCMA CAR-T Launches Phase III Clinical Trial
Gilead (GILD.US) and ArcellX registered a phase III clinical trial of Anitocabtagene Autoleucel for the treatment of recurrent or refractory multiple myeloma on the ClinicalTrials.gov website.
Market Whales and Their Recent Bets on GILD Options
Financial giants have made a conspicuous bullish move on Gilead Sciences. Our analysis of options history for Gilead Sciences (NASDAQ:GILD) revealed 13 unusual trades.Delving into the details, we foun
Gilead Sciences, Inc. (GILD) BofA Securities 2024 Health Care Conference (Transcript)
Gilead Sciences, Inc. (GILD) BofA Securities 2024 Health Care Conference (Transcript)
Analysis
Price Target
No Data
